Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, announced today that the introduction of generic forms of Claritin (Schering-Plough's loratadine) will reduce the United States antihistamine market by 15% over the next ten years. According to the new report entitled Allergic Rhinitis, the availability of over-the-counter nonsedating antihistamines will reduce the prescription drug-treated population in the U.S. from 95% of the diagnosed cases in 2001 to 80% in 2011.
"The historically lucrative allergic rhinitis market is on the verge of major transitions, particularly in the United States," said Daqing Hartwell, Director of the Immune and Inflammatory Disorders Service at Decision Resources. "On the one hand, generic substitutions and possible prescription to over-the-counter switches of major products threaten to reduce the market size for prescription drugs. On the other hand, the recently published Allergic Rhinitis and Its Impact on Asthma report endorsed by the World Health Organization (WHO) encourages early treatment of allergic rhinitis in order to prevent asthma exacerbations. This recommendation may lead to an increase in the number of patients treated with nasal corticosteroids and also encourages the development of combination therapies."
Disease Facts - Allergic Rhinitis
Allergic rhinitis is a highly attractive disease target for pharmaceutical companies because it affects nearly 150 million people in the world's seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Most people with allergic rhinitis self-medicate with nonprescription "first-generation" antihistamines and/or decongestants. According to allergy experts interviewed by Decision Resources, only 30-45% of allergic rhinitis patients are actually diagnosed with the condition by a physician. Consequently, there is a vast untapped market of allergic rhinitis sufferers who could benefit from prescription medications that either are more potent or produce fewer side effects than available over-the counter drugs.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Allergic Rhinitis is an Immune and Inflammatory Disorders report.
About Decision Resources
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.decisionresources.com/.
All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 email@example.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,
Web site: http://www.dresources.com/